CTOs on the Move

Shipt

www.shipt.com

 
Through a community of shoppers and a convenient app, Shipt provides personal shopping and delivery and is available to 80% of households in more than 5,000 U.S. cities. Shoppers go above and beyond, communicating in real time about preferences and substitutions. A curated marketplace of retailers, Shipt offers access to a variety of stores and product categories including fresh foods, household essentials, wellness products, office and pet supplies. Shipt is an independently operated, wholly owned subsidiary of Target Corp. Founded and headquartered in Birmingham, Alabama, Shipt also maintains an office in San Francisco.
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million
  • www.shipt.com
  • 420 20th Street North Suite 100
    Birmingham, AL USA 35203
  • Phone: 205.502.2500

Executives

Name Title Contact Details
Smrutha Ipparthi
 Chief Technology and Product Officer Profile
Jarrod Petrovics
 Director of Information Security Profile

Funding

Shipt raised $20M on 07/28/2016
Shipt raised $40M on 06/05/2017

Similar Companies

Bitfocus

Our expertise and industry-leading Clarity Human Services software allow you to effortlessly coordinate housing and services within your community.

Numara Software

Numara Software is a Tampa, FL-based company in the Software and Internet sector.

Instinctive

We work on projects that improve digital advertising and online privacy.

LogicStream Health

LogicStream Health provides Clinical Process Improvement software to help clinical and pharmacy teams improve workflows and reduce costs.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.